NervGen Pharma Welcomes Neil Klompas To Its Board Of Directors

NervGen Pharma Corp., a biotech firm focused on advancing treatments for nervous system injuries, has revealed the addition of Mr. Neil Klompas to its Board of Directors. Glenn Ives, NervGen’s Chairman, stated, “We are very pleased that Neil is joining our Board at a pivotal time, as we prepare for future growth. His substantial expertise of over two decades in US and Canadian finance, licensing, and mergers and acquisitions, as well as his operational experience in building start-up biotech companies with multiple development programs, will be a valuable addition to the company.”

Mr. Klompas expressed his excitement by saying, “I am very excited to work with NervGen’s Board and executive management team to advance the company’s pipeline which offers new hope for patients suffering from nervous system damage and neurodegenerative diseases. NVG-291, which is currently in a Phase 1b/2a clinical trial in individuals with spinal cord injury, is a unique, first-in-class drug candidate and I look forward to doing my part in driving NervGen’s mission forward and helping realize the potential of this innovative therapy.”

Mr. Klompas brings a wealth of experience to the life sciences and healthcare sectors, having recently held the role of President and Chief Operating Officer at Zymeworks Inc. There, he played a pivotal role in managing finance and operations, including the successful execution of the company's IPO on both the NYSE and TSX. Before his tenure at Zymeworks, Mr. Klompas contributed his expertise to KPMG LLP in their Pharmaceutical, Biotech & Medical Devices M&A Transaction Services practice in Princeton, NJ, and also worked in the life sciences assurance practice in Vancouver.

He has also held significant positions such as Board Chair at Ovensa Inc. and Chair of the Audit and Special Committees at Liminal Biosciences Inc., until its acquisition in 2023. Mr. Klompas earned his BSc in Microbiology & Immunology from the University of British Columbia and is a Chartered Professional Accountant. In related news, the company has awarded Mr. Klompas 150,000 incentive stock options, each exercisable at $2.85 per share over five years, with vesting occurring equally every three months over the first year. These options comply with the TSX Venture Exchange policies and the company's stock option plan.